Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Standard BioToolsSTU:FLB -6.29%39 Altman Z-Score is 0.71 as of Jul. 14, 2026. GuruFocus rates STU:FLB with a GF Score™ of 39/100 and a GF Value™ of €0.46 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 809 Medical Devices & Instruments companies, Standard BioTools ranks worse than 74.78% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of 0.66 is in distress zone. This implies bankruptcy possibility in the next two years.
Standard BioTools has a Altman Z-Score of 0.71, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Standard BioTools's Altman Z-Score or its related term are showing as below:
STU:FLB'
s Altman Z-Score Range Over the Past 10 Years
Min: -4.36 Med: -2 Max: 2.3
Current: 0.66
During the past 13 years, Standard BioTools's highest Altman Z-Score was 2.30. The lowest was -4.36. And the median was -2.00.
Standard BioTools (STU:FLB) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Standard BioTools Altman Z-Score Related Terms
Standard BioTools Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Standard BioTools's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:FLB vs SENS, TMCI, SGHT: Altman Z-Score Comparison
For the Medical Devices subindustry, Standard BioTools's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Standard BioTools Altman Z-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Standard BioTools's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Standard BioTools's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Standard BioTools's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.7499
+
1.4
*
-1.7735
+
3.3
*
-0.1362
+
0.6
*
4.3408
+
1.0
*
0.1341
=
0.71
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Standard BioTools (STU:FLB) has a Altman Z-Score of 0.71 as of Jul. 14, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Standard BioTools and its competitors. According to the industry distribution chart, Standard BioTools ranks #605 out of 809 companies in the Medical Devices & Instruments industry, placing it in the top 74.8%.
Is Standard BioTools' Altman Z-Score too high?
Standard BioTools' current Altman Z-Score is 0.71. The Medical Devices & Instruments industry median Altman Z-Score is 3.02. Standard BioTools' value of 0.71 is 76.5% below this industry median. Based on the distribution chart, Standard BioTools ranks #605 out of 809 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Standard BioTools has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Standard BioTools' Altman Z-Score compare to SENS and TMCI?
According to the Medical Devices & Instruments industry distribution chart, Standard BioTools ranks #605 out of 809 companies for Altman Z-Score. This places Standard BioTools in the lower half of its industry. The industry median Altman Z-Score is 3.02. Standard BioTools' value of 0.71 is 76.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Devices & Instruments company?
The median Altman Z-Score among Medical Devices & Instruments companies is 3.02, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Standard BioTools's current Altman Z-Score of 0.71 is 76.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Standard BioTools and its competitors. For the Medical Devices & Instruments industry, the median Altman Z-Score is 3.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Standard BioTools's current Altman Z-Score is 0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard BioTools stock overvalued right now?
Based on GuruFocus' analysis, Standard BioTools (STU:FLB) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.46, compared to a current price of €0.75 — trading 62% above its estimated fair value. The current Altman Z-Score is 0.71 and 76.5% below the Medical Devices & Instruments industry median of 3.02. Standard BioTools' overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Standard BioTools (STU:FLB), the current Altman Z-Score is 0.71 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Standard BioTools (STU:FLB) Overvalued in 2026?
Based on GuruFocus' analysis, Standard BioTools stock appears to be overvalued.
The current stock price of €0.75 is trading 62% above its estimated GF Value™ of €0.46.
GuruFocus considers Standard BioTools to be Significantly Overvalued.
Key valuation signals for STU:FLB:
Altman Z-Score: 0.71
GF Value™: €0.46 vs. price of €0.75 (62% above fair value)
Industry Position: 76.5% below the Medical Devices & Instruments median (#605 of 809)
No single metric tells the full story. See the STU:FLB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
39GF Score
Get the complete analysis for STU:FLB
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:FLB has been successfully added to your 
